$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000106282215000039 Filed on November 09, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$566.0K	$21.48M	$419.0K
YoY Change	35.08%	1423.55%	76.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.400M	$4.000M	$4.500M
YoY Change	20.0%	17.65%	-4.26%
% of Gross Profit
Research & Development	$23.11M	$20.00M	$24.11M
YoY Change	-4.14%	-1.48%	-5.09%
% of Gross Profit
Depreciation & Amortization	$100.0K	$200.0K	$500.0K
YoY Change	-80.0%	-71.43%	-16.67%
% of Gross Profit
Operating Expenses	$34.24M	$24.90M	$40.76M
YoY Change	-15.98%	35.33%	29.57%
Operating Profit	-$33.68M	-$3.447M	-$40.34M
YoY Change	-16.51%	-79.69%	29.22%
Interest Expense	$1.687M	-$900.0K	$449.0K
YoY Change	275.72%	80.0%	-8.74%
% of Operating Profit
Other Income/Expense, Net	$82.00K	$1.300M	$287.0K
YoY Change	-71.43%		2509.09%
Pretax Income	-$35.30M	-$3.000M	-$40.50M
YoY Change	-12.84%	-82.76%	27.76%
Income Tax		-$100.0K	$0.00
% Of Pretax Income
Net Earnings	-$35.28M	-$2.933M	-$40.50M
YoY Change	-12.88%	-83.16%	27.92%
Net Earnings / Revenue	-6233.57%	-13.65%	-9665.39%
Basic Earnings Per Share	-$0.34
Diluted Earnings Per Share	-$0.34	-$34.16K	-$551.0K
COMMON SHARES
Basic Shares Outstanding	103.6M shares	514.8M shares	514.8M shares
Diluted Shares Outstanding	103.6M shares

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$256.0M	$338.9M	$57.40M
YoY Change	345.99%	163.33%	-61.94%
Cash & Equivalents	$61.67M	$137.3M	$26.78M
Short-Term Investments	$194.3M	$201.6M	$30.70M
Other Short-Term Assets	$10.95M	$4.764M	$5.937M
YoY Change	84.49%	2.76%	-18.19%
Inventory
Prepaid Expenses
Receivables	$72.00K	$1.035M	$165.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$288.9M	$369.0M	$87.82M
YoY Change	229.02%	174.23%	-44.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$795.0K	$1.080M	$1.494M
YoY Change	-46.79%	-97.39%	-96.43%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.36M	$53.36M	$53.56M
YoY Change	-0.37%	-0.37%	0.0%
Long-Term Investments
YoY Change
Other Assets	$3.498M	$3.409M	$108.0K
YoY Change	3138.89%	2267.36%	-31.65%
Total Long-Term Assets	$102.2M	$102.4M	$99.70M
YoY Change	2.5%	-26.66%	-28.83%
TOTAL ASSETS
Total Short-Term Assets	$288.9M	$369.0M	$87.82M
Total Long-Term Assets	$102.2M	$102.4M	$99.70M
Total Assets	$391.1M	$471.4M	$187.5M
YoY Change	108.58%	71.93%	-37.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.36M	$13.06M	$9.741M
YoY Change	67.9%	34.47%	0.33%
Accrued Expenses	$14.91M	$10.12M	$13.13M
YoY Change	13.54%	31.87%	13.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$18.79M	$20.17M	$20.61M
YoY Change	-8.84%	1079.36%	1130.39%
Total Short-Term Liabilities	$51.80M	$44.97M	$44.27M
YoY Change	17.01%	133.07%	87.6%
LONG-TERM LIABILITIES
Long-Term Debt	$87.50M	$87.50M	$0.00
YoY Change		333.88%	-100.0%
Other Long-Term Liabilities	$23.52M	$23.54M	$34.01M
YoY Change	-30.83%	-27.33%	-9.06%
Total Long-Term Liabilities	$111.0M	$111.0M	$34.01M
YoY Change	226.48%	111.28%	-41.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.80M	$44.97M	$44.27M
Total Long-Term Liabilities	$111.0M	$111.0M	$34.01M
Total Liabilities	$193.2M	$187.4M	$109.7M
YoY Change	76.12%	80.16%	-3.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.196B	-$1.104B	-$1.101B
YoY Change	8.57%	9.99%	11.63%
Common Stock	$104.0K	$104.0K	$516.0K
YoY Change	-79.84%	-79.77%	0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.747M	$2.390M	$2.390M
YoY Change	14.94%	59.02%	59.02%
Treasury Stock Shares	237.0K shares	183.0K shares	1.281M shares
Shareholders Equity	$197.9M	$284.0M	$77.82M
YoY Change
Total Liabilities & Shareholders Equity	$391.1M	$471.4M	$187.5M
YoY Change	108.58%	71.93%	-37.38%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$35.28M	-$2.933M	-$40.50M
YoY Change	-12.88%	-83.16%	27.92%
Depreciation, Depletion And Amortization	$100.0K	$200.0K	$500.0K
YoY Change	-80.0%	-71.43%	-16.67%
Cash From Operating Activities	-$25.40M	-$4.400M	-$21.20M
YoY Change	19.81%	-79.82%	-11.3%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$100.0K	$0.00
YoY Change		-50.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$78.00M	-$170.6M	$20.50M
YoY Change	280.49%	-526.5%	0.0%
Cash From Investing Activities	$77.80M	-$170.7M	$20.50M
YoY Change	279.51%	-529.97%	0.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-400.0K	285.7M	-300.0K
YoY Change	33.33%	-285800.0%
NET CHANGE
Cash From Operating Activities	-25.40M	-4.400M	-21.20M
Cash From Investing Activities	77.80M	-170.7M	20.50M
Cash From Financing Activities	-400.0K	285.7M	-300.0K
Net Change In Cash	52.00M	110.6M	-1.000M
YoY Change	-5300.0%	521.35%	-72.22%
FREE CASH FLOW
Cash From Operating Activities	-$25.40M	-$4.400M	-$21.20M
Capital Expenditures	-$200.0K	-$100.0K	$0.00
Free Cash Flow	-$25.20M	-$4.300M	-$21.20M
YoY Change	18.87%	-80.09%	-10.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-27000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	61000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	34000000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103622755	shares
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2015Q3	lxrx	Buildings Collateral BuildingsCollateral	59100000	USD
CY2014Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	-1072000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	518000	USD
CY2015Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	3404000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	5145000	USD
CY2015Q2	lxrx	Common Stock Shares Authorized After Reverse Stock Split CommonStockSharesAuthorizedAfterReverseStockSplit	225000000	shares
CY2015Q2	lxrx	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	900000000	shares
CY2015Q3	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	2300000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2015Q3	lxrx	Land Collateral LandCollateral	2700000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
CY2015Q4	lxrx	Sanofi Commercialization Costs Funded By Lexicon Percentage SanofiCommercializationCostsFundedByLexiconPercentage	0.40
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Developmentand Regulatory Milestone Payments SanofiDevelopmentandRegulatoryMilestonePayments	430000000	USD
CY2015Q4	lxrx	Sanofi Maximum Royalty Percentage SanofiMaximumRoyaltyPercentage	0.40
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	21360	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	7.49
CY2014Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	697000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2389000	USD
CY2015Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	779000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2548000	USD
CY2014Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	797000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3195000	USD
CY2015Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	893000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2865000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13064000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	16355000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1035000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5584000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5413000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10120000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14913000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36274000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17833000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	58000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1390619000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1396207000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5600000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5400000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	37000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	380000	USD
CY2014Q4	us-gaap	Assets Assets	471376000	USD
CY2015Q3	us-gaap	Assets Assets	391140000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	368987000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	288947000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26775000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137266000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61674000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10724000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-75592000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	128571000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40501000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97361000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35322000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-91311000	USD
CY2014Q3	us-gaap	Contracts Revenue ContractsRevenue	312000	USD
	us-gaap	Contracts Revenue ContractsRevenue	1111000	USD
CY2015Q3	us-gaap	Contracts Revenue ContractsRevenue	505000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2635000	USD
CY2015Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2015Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	129800000	USD
CY2015Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2014Q4	us-gaap	Debt Issuance Costs DebtIssuanceCosts	3400000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1618000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1743000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11708000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2015Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1724000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	661000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	518000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	5145000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-750000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
CY2014Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28228000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17638000	USD
CY2015Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22033000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-811000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4617000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15423000	USD
CY2014Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	13102000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	13102000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13344000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2349000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5379000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17387000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q3	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q3	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4200000	USD
CY2015Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	2349000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	2349000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6587000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2924000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-625000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-963000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	136000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	846000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-469000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1301000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6189000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	449000	USD
	us-gaap	Interest Expense InterestExpense	1361000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	1687000	USD
	us-gaap	Interest Expense InterestExpense	5044000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1355000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3586000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	187358000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	193202000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	471376000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391140000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44969000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	51799000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	107000	USD
	us-gaap	Licenses Revenue LicensesRevenue	261000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	61000	USD
	us-gaap	Licenses Revenue LicensesRevenue	99000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20167000	USD
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	18788000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q3	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	18800000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1857000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	34243000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40336000	USD
	us-gaap	Operating Expenses OperatingExpenses	89626000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1561000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62297000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7117000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71164000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81148000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-40498000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97361000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-35282000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-91432000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	40755000	USD
	us-gaap	Operating Expenses OperatingExpenses	98291000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-96919000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33677000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-86892000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4764000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	10953000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3409000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3498000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-40000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	121000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23535000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23520000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	287000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	919000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	82000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	504000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	357000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	82554000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	664000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73542000	shares
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	325000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	114000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	81186000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	90000000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1808000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	335000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1080000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	795000	USD
CY2014Q4	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
CY2015Q3	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	21500000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1268000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1379000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24108000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69248000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23111000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64745000	USD
CY2014Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2015Q3	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1104252000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1195684000	USD
CY2014Q3	us-gaap	Revenues Revenues	419000	USD
	us-gaap	Revenues Revenues	1372000	USD
CY2015Q3	us-gaap	Revenues Revenues	566000	USD
	us-gaap	Revenues Revenues	2734000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5584000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5413000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	202073000	USD
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	194748000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	325000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	114000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	197938000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2014Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	77824000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	284018000	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	197938000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	61000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	183000	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	237000	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2747000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	357000	USD
CY2015Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2900000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	121000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103616000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73494000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103580000	shares

Files In Submission

Name	View Source	Status
0001062822-15-000039-index-headers.html	Edgar Link	pending
0001062822-15-000039-index.html	Edgar Link	pending
0001062822-15-000039.txt	Edgar Link	pending
0001062822-15-000039-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20150930.xml	Edgar Link	completed
lxrx-20150930.xsd	Edgar Link	pending
lxrx-20150930_cal.xml	Edgar Link	unprocessable
lxrx-20150930_def.xml	Edgar Link	unprocessable
lxrx-20150930_lab.xml	Edgar Link	unprocessable
lxrx-20150930_pre.xml	Edgar Link	unprocessable
lxrx930201510-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q3 Form 10-Q Financial Statement

#000106282215000039 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q3 Form 10-Q Financial Statement

#000106282215000039 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx